Global Protein Labeling Market

CRISPR Technology Market Definition

The CRISPR technology market consists of sales of CRISPR technology products and related services by entities (organizations, sole traders and partnerships) that produce CRISPR technology products and equipment. CRISPR is a genome-editing tool. It is used by researchers/healthcare professionals to alter DNA sequences and modify gene function. CRISPR is also used for correcting genetic defects, treating human diseases, and to yield better crop varieties. CRISPR stands for Clusters Of Regularly Interspaced Short Palindromic Repeats. The CRISPR-Cas9 system consists of two key molecules, — Cas9 and guide RNA, that introduce a change or mutation into the DNA at the desired position. The Cas9 is an enzyme that acts as a pair of ‘molecular scissors’ and can cut the two strands of DNA at a specific location in the genome so that bits of DNA can then be added or removed. The guide RNA (gRNA is a small piece of pre-designed RNA sequence (about 20 bases long) located within a longer RNA scaffold. The scaffold part binds to DNA and the pre-designed sequence ‘guides’ Cas9 to the right part of the genome. This makes sure that the Cas9 enzyme cuts at the right point in the genome. High orthogonality, versatility, and efficiency of CRISPR technology make it a preferred genome editing technology.

The bioinformatics market consists of sales of bioinformatics and related services. Bioinformatics combines computer programming, information engineering, mathematics, and statistics to analyze biological data for drug discovery and for preclinical studies. The bioinformatics market covered in this report is segmented by products and serivces into knowledge management tools, data analysis platforms, services. The bioinformatics market is also segmented by application into metabolomics, molecular phylogenetics, transcriptomics, proteomics, chemoinformatics, genomics, others and by end users into pharmaceutics, animal study, agriculture, forensic science, other end users. The global bioinformatics market is expected to grow from $9.38 billion in 2020 to $10.57 billion in 2021 at a compound annual growth rate (CAGR) of 12.7%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The bioinformatics market is expected to reach $18.46 billion in 2025 at a CAGR of 15%. Increasing demand for protein sequencing is driving growth in the bioinformatics market. Protein sequencing refers to the process of determining the sequence of amino acids in all or part of the proteins present in DNA, based on which specific functions, activities, origin or localization of the protein is determined. Protein sequencing helps analysts to understand the distribution of amino acids along the sequences and the structure of proteins. With bioinformatics methods and databases, capacity, structure and developmental history of proteins can be effectively identified. The demand for protein sequencing is expected to grow on account of factors such as advancements in clinical mass spectrometry and analytical techniques, and significant adoption of target-based drug development by pharmaceutical and biotechnology companies. For instance, the total number of protein sequences in UniProtKB, which is a freely accessible database of protein sequence and functional information, increased by over 325%. Lack of interoperability among various available data formats is acting as a restraint on the bioinformatics market. Various data formats come with differences in structures of data. There are numerous protein databases available through various resources, and each database chooses to represent proteins in a different format. Also, different data models such as object data model or relational data model are used while collecting data. Therefore, the problem of interoperability arises when a researcher tries to integrate the results of unique databases present in different data formats. Various data formats available for bioinformatics include Compressed Row Storage (CRS), Sparse Vector, Avro, Parquet and ORC (Optimized Row Compressed). According to a report by Pharmaphorum, an estimated 80% of the researchers’ time is spent on data grooming and only 20% on actual data analysis. This is essentially due to the lack of standardized file types and inconsistent data formatting, which means that every new program results in a new data format. The interoperability issues arising from the use of multiple data formats is affecting market growth. Companies in the bioinformatics market are increasingly investing in the research and development of nanopore sequncing technology. Nanopore sequencing is a single molecule DNA sequencing technology which eliminates the need for Polymerase Chain Reaction or chemical labelling of the sample. This technology passes ionic current through nanopores (a pore of nanometer size) and when the biological molecules pass through the nanopores or near to it then this technology measures the changes in current which can be used to identify the molecule. Nanopore sequencing technology offers high throughput, low cost, longer reads (Sequence of a section of a unique fragment) to the analyst and helps in the collection of data which is an essential part of bioinformatics. For instance, Oxford Nanopore Technologies raised $140 million for commercial expansion and support for further research and development in the area of nanopore technology. Also, biotechnology company Amgen invested $66 million in the company. The bioinformatics market is governed by various regulatory bodies for quality and compliance of bioinformatics platforms. For instance, in India, the Biotechnology Industry Research Assistance Council (BIRAC), set up by Department of Biotechnology (DBT), Government of India, regulates the bioinformatics market. BIRAC introduces Technology Readiness Levels (TRLs) as a measure of estimating the maturity of technology while in the evaluation phases until these technologies are complete to be offered commercially. The TRL scale provides 9 technology readiness levels with TRL1 being the stage when the technology is ideated, and TRL9 being the stage when the technology is ready for commercial use. The manufacturers have to get past TRL9 to have their product available commercially and ready to be marketed. These TRL's consist of various levels of compliance and processes that the manufacturers must adhere to. The bioinformatics platform is evaluated for quality, feasibility, data privacy and protection as per international standards. In September 2020, APIS Assay Technologies Ltd, a UK based Biotechnology company acquired BeoGenomics for an undisclosed amount. With the addition of Beogenomics’ proven expertise in bioinformatics APIS Assay Technologies Ltd can more effectively capture the exciting opportunities presented in the bioinformatics space. BeoGenomics, a USA based bioinformatics company that focuses on NGS, SNP chip and GeneChip genomic data processing and analysis. Major players in the bioinformatics market are Agilent Technologies, Illumina, QIAGEN, Affymetrix and Thermo Fisher Scientific. The regions covered in the bioinformatics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the bioinformatics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global bioinformatics market is segmented - 1) By Products and Serivces: Knowledge Management Tools, Data Analysis Platforms, Services 2) By Application: Metabolomics, Molecular Phylogenetics, Transcriptomics, Proteomics, Chemoinformatics, Genomics, Others 3) By End Users: Pharmaceutics, Animal Study, Agriculture, Forensic Science, Other End Users

The metabolomics market consists of sales of metabolomics analytical tools, equipment and related services. Metabolomics is the field of bio-analytics for quantification and identification of metabolic small molecules such as cell, tissue, organ and biological fluid. Metabolomics includes analytical instruments such as liquid chromatography, gas chromatography, capillary electrophoresis, mass spectrometry and nuclear magnetic resonance spectroscopy. The metabolomics market covered in this report is segmented by product & service into metabolomics instruments, metabolomics bioinformatics tools & services. The metabolomics market is also segmented by application into biomarker discovery, drug discovery, toxicology testing, nutrigenomics, functional genomics, personalized medicine, others; by indication into cancer, cardiovascular disorders, neurological disorders, inborn errors of metabolism, others; by metabolomics instruments into separation techniques, detection techniques; by metabolomics bioinformatics tools & services into bioinformatics tools and database, bioinformatics services. The global metabolomics market is expected to grow from $2.03 billion in 2020 to $2.26 billion in 2021 at a compound annual growth rate (CAGR) of 11.3%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The metabolomics market is expected to reach $3.6 billion in 2025 at a CAGR of 12.3%. Increasing prevalence rate of cancer drives the metabolomics market growth. Metabolomics screens the potential biomarkers (specific cells, molecules, or genes, gene products, enzymes, or hormones) to measure the cancer drug responsiveness aiding early diagnosis. For instance, according to a report by American Cancer Society in 2019, approximately 1,762,450 new cancer cases were diagnosed in the United States of which the most common cancers are lung cancer, breast cancer, prostate cancer and others. In 2020, according to American Cancer Society, lung cancer is the leading cancer killer in both men and women in the USA, there were 228,820 new cancer cases and 135,720 deaths. Metabolomics approaches such as nuclear magnetic resonance (NMR) technique and mass spectrometry (MS) techniques have been used to study cancer. Companies like Metabolon Inc., Bruker Corp, and others have adopted metabolomics as a tool for early detection and cure for cancer. The increasing complexity in interpreting data act as a restraint hindering the metabolomics market growth. Metabolomics tools generate huge quantum of data through metabolomics techniques and the generated data keeps changing not static, hence increasing the difficultly in interpretation of data. For instance, data generated by nuclear magnetic resonance (NMR) Spectroscopy, an analytical technique used for metabolic profiling (a method to measure and interpret various low molecular weight and other intermediates), is difficult to process and interpret. High-level statistical techniques are required for classification and analysis of this data to uncover the biological knowledge which is time-consuming and expensive, restraining the metabolomics market growth. Machine learning is increasing its popularity in the field of metabolomics due to improve efficiency in interpretation of data generated from metabolomics techniques. Machine learning enabled technologies help in automation of risky and complex processes, avoid repetitive and time taking processes, provide quick and error-free services. Companies in the industry are preferring machine learning techniques for metabolism analysis to solve problems, automate processes and execute tasks. Some of the machine learning algorithms aid in metabolism data analysis and metabolic pathway modelling. Some of the companies such as Bio-Rad Laboratories, Metabolon Inc and others have started using machine learning algorithms for better understanding and prediction in metabolomics study. For instance, MeltDB 2.0, a machine learning software used as a tool for the analysis and integration of metabolomics experiment data that aids research, store experimental data sets. Such machine learning software offer comprehensive analysis and visualization features for the proper representation of the large complex data. In January 2018, Biocrates Life Sciences AG, an Austria-based biotechnology company, acquired Metanomics Health GmbH, for an undisclosed amount. This acquisition would strengthen and improve Biocrates Life market share in early disease detection by leveraging the capabilities of Metanomics. Metanomics Health GmbH is a biotechnology company offering metabolomics in life sciences, providing analytical services of metabolite profiling, involved in marketing and developing tools to carry out research and development in healthcare sector. The company was founded in 2002 and is headquartered in Berlin, Germany. Major players in the metabolomics market are Human Metabolome Technologies, Metabolon, Bio-Rad Laboratories, Bruker and Agilent Technologies. The regions covered in the metabolomics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the metabolomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global metabolomics market is segmented - 1) By Product & Service: Metabolomics Instruments, Metabolomics Bioinformatics Tools & Services 2) By Application: Biomarker Discovery, Drug Discovery, Toxicology Testing, Nutrigenomics, Functional Genomics, Personalized Medicine, Others 3) By Indication: Cancer, Cardiovascular Disorders, Neurological Disorders, Inborn Errors Of Metabolism, Others 4) By Metabolomics Instruments: Separation Techniques, Detection Techniques 5) By Metabolomics Bioinformatics Tools & Services: Bioinformatics Tools And Databases, Bioinformatics Services

The synthetic biology market consists of sales of synthetic compound, technology and related services. Synthetic biology is a field of biology science which involve engineering principles. The synthetic biology market covered in this report is segmented by technology into nucleotide synthesis and sequencing, bioinformatics, microfluidics, genetic engineering. The synthetic biology market is also segmented by application into pharmaceuticals and diagnostics, chemicals, biofuels, bioplastics, others and by product type into oligonucleotides, enzymes, cloning and assembly kits, xeno-nucleic acids (XNA), chassis organism. The global synthetic biology market is expected to grow from $8.64 billion in 2020 to $10.07 billion in 2021 at a compound annual growth rate (CAGR) of 16.6%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The synthetic biology market is expected to reach $28.91 billion in 2025 at a CAGR of 30.2%. DNA sequencing is important in development of the synthetic biology in many ways. The DNA sequencing finds its use in many synthetic biology applications, therefore the availability of the DNA sequencing technique at low cost drives the production of products based on the applications of synthetic biology. DNA sequencing allows the researchers to determine the DNA sequences in genes and helps a researcher to create a repository of entire genomes. These repositories form the basis for the implementation of synthetic biology applications such as protein expression, directed evolution, and metabolic engineering. According to the World Economic Forum report in 2019, costs per genome sequenced have been decreased from $3 billion to less than $1,000 over the past 15 years and are projected to be gradually lowered by 10 times over the next five years. The bio-safety risks involved in synthetic biology restrains the synthetic biology market. Synthetic biology involves researches on micro-organism to perform the desired function or produce a biological desired substance. Such processes possess health risks such as illness, allergies in humans as well as environmental risks such as toxicity and risk of new micro-organisms affecting living creatures in the ecosystem. Such potential risks pose as a deterrent to possible innovative research that could be done in certain fields such as combating epidemics such as Ebola and life-threatening diseases such as cancer. The new technological advances in the field of DNA sequencing has enabled the researchers to use DNA to store non-genetic information. With the rise in the demand to store quantum of data, DNA data storage offers a solution where one DNA strand can store about 455 Exabyte of data (455 billion gigabytes). Thus, the concept has received huge investments from the entities in the market. The binary data (data coded in 0O and 1) is converted into DNA strings of four potential base units of unique sequences of A, G, C, T (DNA is made up of four base components: Adenine, Guanine, Cytosine, and Thymine (known as AGCT)). The information coded in DNA lasts for thousands of years when compared to the data in traditional hard drives which gets corrupted or damaged within 30 years. For instance, according to a journal published by Nature Publishing Group, Microsoft and University of Washington researchers stored 35 distinct digital files in DNA—more than 200 megabytes of data and plans to increase future investment to improve the technology. In March 2020, Zymergen, a California based material innovation company rethinking biology and reimagining the world acquired enEvolv, Inc. for an undisclosed amount. This acquisition speeds Zymergen delivery of high performance and sustainable products to customers and further cements Zymergen leadership position in the bio-manufacturing space. enEvolv, Inc, a next-generation synthetic biology company that has developed an enzyme and strain development platform to harness the power of evolution and create unique, commercial products by engineering the genomes of microbes. Major players in the synthetic biology market are Thermo Fischer Scientific, Genscript, Integrated DNA Technologies, Amyris and Twist Bioscience Corporation. The regions covered in the synthetic biology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the synthetic biology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global synthetic biology market is segmented - 1) By Technology: Nucleotide Synthesis And Sequencing, Bioinformatics, Microfluidics, Genetic Engineering 2) By Application: Pharmaceuticals And Diagnostics, Chemicals, Biofuels, Bioplastics, Others 3) By Product Type: Oligonucleotides, Enzymes, Cloning And Assembly Kits, Xeno-Nucleic Acids (XNA), Chassis Organism

The protein expression market consists of sales of protein expression vectors, competent cells, reagents, equipment and related services. Protein expression is a process in which proteins are synthesized, modified, regulated and controlled in living organisms according to the host cell. Protein expression included yeast expression, insect expression, and bacterial expression, algal expression and mammalian cell expression. The protein expression market covered in this report is segmented by protein expression into yeast expression, mammalian expression, algae expression, insect expression, bacterial expression, cell-free expression. The protein expression market is also segmented by end use into pharmaceutical and biotechnological companies, academic research, contract research organizations; by product into reagents, competent cells, expression vectors, services, instruments; by application into therapeutic, industrial, research. The global protein expression market is expected to grow from $2.01 billion in 2020 to $2.13 billion in 2021 at a compound annual growth rate (CAGR) of 6%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The protein expression market is expected to reach $3.03 billion in 2025 at a CAGR of 9.2%. Increase in demand for biologics to counter various genetic disorders and chronic diseases is one the major factors driving the research and sales of protein expression market. Biologics is a medicine produced from living organisms or contains components of living organisms such as protein, tissue, genes, allergens, cells, blood components, blood, and vaccines. The increasing use of biologics (therapeutic protein and others) to cure chronic diseases such as cancer, cardiovascular conditions and genetic disorders, is increasing the demand for protein expression devices and equipment. According to the World Health Organization, chronic disease prevalence is expected to rise by 57% globally, by the year 2020. Hence the rising demand for biologics is driving the protein expression market. For instance, according to an article published by Chemistry World, analysts expect the biologics market to hold a market share of more than a quarter of the entire pharmaceutical market by 2020. The global biologics market is expected to grow at 9.9% during 2018-2024. Government regulations related to protein therapeutics and production of biologics may hinder the protein expression market growth. Government regulations on biologics to undergo rigorous preclinical and clinical trials prior to regulatory approval, and time consuming process for approval of biologics with regards to health and the safety of any individual are restraining the market growth. Marketing and distribution of biologics including insulin, hormones, therapeutic antibodies, and vaccines depends upon the successful completion of clinical trials, which is a long, expensive, and uncertain process. According to FDA, for an approval of new biologic, Under the regulations (21 CFR 314.81(b)(2)(vii) and 601.70, a clinical trial approval usually takes 10- 12 months where firms are required to submit a report annually on the status of clinical safety, clinical efficiency, clinical pharmacology, and nonclinical toxicology study. Companies in the industry are increasingly adopting Microfluidics technology to enhance protein expression tests in order to reduce the time, cost, labor, and increase the accuracy and performance. The microfluidics technology effectively analyzes biological samples than the traditional (macroscale) instruments. Microfluidics technology is used to measure the expression of proteins on cells and optimizes the output to generate results regarding protein expression. Therapeutics-on-a-chip (TOC) uses microfluidic platform and is able to synthesize proteins in a point of care setting to reduce cost associated with storage and transportation of therapeutic proteins. For instance, companies such as MissionBio, NanoCellect Biomedical, RainDance Technologies and Sphere fluidics have implemented this technology in protein expression test. The Protein Expression market in the U.S. is governed by Food and Drug Administration (FDA) that lays down a series of guidelines for the manufacturers and retailers of this industry. Within FDA, Center for Drug Evaluation and research (CDER) regulates biological products under FDA 101 which includes gene therapy products and vaccines. These regulations ensure quality, safety and efficacy of biological therapeutics products, and speed up innovations that make these products safer, and effective. The US’s FDA announced a fast-track initiative to review its drugs and biologics policy to speed the availability of therapies to patients with serious conditions, orphan drugs for rare disease, while preserving the safety and efficacy standards. FDA also removed a rule (Section 610.21 of the FDA code) which specified minimal potency limits for certain antibodies and antigens. The European Medicines Agency has also introduced policies which include a provision to waive the scientific advice fee, which encourage more academic groups and small companies to propose candidates for biologics. Major players in the protein expression market are Agilent Technologies, Bio-Rad Laboratories, Thermo Fisher Scientific Inc., New England Biolabs and Promega Corporation. The regions covered in the protein expression market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the protein expression market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global protein expression market is segmented - 1) By Protein Expression: Yeast Expression, Mammalian Expression, Algae Expression, Insect Expression, Bacterial Expression, Cell-free Expression 2) By End Use: Pharmaceutical And Biotechnological Companies, Academic Research, Contract Research Organizations 3) By Product: Reagents, Competent Cells, Expression Vectors, Services, Instruments 4) By Application: Therapeutic, Industrial, Research

The protein labeling market consists of sales of protein labeling products and related services by entities (organizations, sole traders and partnerships) that produce protein labeling products to diagnose various diseases. Protein labeling refers to the use of appropriate molecular labels to detect or purify proteins and their binding partners in tissues, cells, and biochemical assays. The protein labeling market covered in this report is segmented by product into reagents, protein, enzymes, probes/ tags, monoclonal antibodies; by labeling method into in-vitro labeling, in-vivo labeling; by application into cell based-assay, fluorescence microscopy, immunological techniques, mass spectrometry, protein microassay. The global protein labeling market is expected to grow from $1.6 billion in 2020 to $1.77 billion in 2021 at a compound annual growth rate (CAGR) of 10.6%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The protein labeling market is expected to reach $2.79 billion in 2025 at a CAGR of 12%. Increased spending on the R&D of proteomics and genomics is driving the growth of the protein labeling reagents market. Proteomics is the study of the overall protein content of a cell, tissue, or organism. Protein labeling methods before separation and analysis is essential during proteomic profiling approaches. For instance, the National Institutes of Health (NIH) of the United States, funded $37 billion for biomedical research. This funding is for life sciences research that supports study at a molecular level for the understanding of fundamental processes by which diseases develop identification of biomarkers that signal the presence of disease, or identification of gene/protein responsible for the disease. The Novo Nordisk Foundation granted a grant of up to $1.5 million to the University of Copenhagen to establish a mass spectrometry facility, which marks a new and exciting step in protein research. Therefore, the increased spending on research and development of proteomics and genomics is driving the market. Drawbacks related to protein labeling techniques are expected to hinder the market. Label-free techniques are preferred over labeled techniques because of the drawbacks associated with them, such as wet-lab complexity and flexibility. While label-free samples can be measured without much preparation, wet lab pre-treatment is required for all labeling techniques. Samples must be labeled with metabolic (e.g. SILAC) or chemical (e.g. iTRAQ or TMT) reagents and the different conditions has to be combined. Therefore, label-free techniques are less prone to wet lab errors than labeling techniques. Label-free approaches have the advantage of being highly adaptable even after the study has begun. New samples can be included at any time, but labeled approaches require the same number (n) of each condition. New samples may not be included in the study if they cannot be physically mixed and measured together with the control. Labeled techniques such as the "Super-SILAC" approach reduce this problem but must also be carefully planned. These disadvantages are making label-free techniques preferable. Therefore, drawbacks associated with protein labeling techniques are expected to hinder the market. Companies in the protein labeling market are increasing their product innovation through strategic collaborations. To sustain in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated with each other as well as academic and research institutions in this market by way of partnerships, in or out-licensing deals, this trend has been increasing over recent years. For instance, in 2018 recombinant protein manufacturer enGenes Biotech GmbH (enGenes) announced a collaboration with ACIB GmbH for protein labeling. In January 2020, Abcam, a UK-based protein research tools producer and seller, announced its decision to acquire Expedeon's Proteomics and Immunology business, which includes Innova and TGR Biosciences. Expedeon technology supports a diverse set of labels, including enzymes, metals, oligos, and fluorescent proteins. Abcam will combine the newly acquired capture and conjugation technologies with its extensive antibody and protein expertise to expand and enhance its portfolio of off-the-shelf, and custom reagents and tools. Expedeon is a Germany-based manufacturer of protein discovery and analysis products used for protein and drug research. Major players in the protein labeling market are Thermo Fisher Scientific Inc, Merck KGaA, PerkinElmer, Inc., General Electric Company, F. Hoffmann-La Roche AG, AGILENT TECHNOLOGIES INC., BIO-RAD LABORATORIES, Kirkegaard & Perry Laboratories, LI-COR Inc., and Kaneka Corporation. The regions covered in the protein labeling market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the protein labeling market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global protein labeling market is segmented - 1) By Product: Reagents, Protein, Enzymes, Probes/ Tags, Monoclonal Antibodies 2) By Labeling Method: In-vitro Labeling, In-vivo Labeling 3) By Application: Cell Based-Assay, Fluorescence Microscopy, Immunological Techniques, Mass Spectrometry, Protein Micro Assay

The protein inhibitors market consists of sales of protein inhibitors by entities (organizations, sole traders, and partnerships) that are engaged in the manufacturing of protein inhibitors. Protein synthesis inhibitors stop the development of cells by disrupting the process leading to the generation of new proteins. Protein inhibitors is a pharmaceutical drug that acts on the proteins (special target) in the body and finds applications in the treatment of various diseases such as cancer, autoimmune diseases, infectious diseases, and others. The global protein inhibitors market is expected to grow from $56.97 billion in 2020 to $62.54 billion in 2021 at a compound annual growth rate (CAGR) of 9.8%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $88.74 billion in 2025 at a CAGR of 9%. The increasing prevalence of chronic diseases is predicted to contribute to the growth of the protein inhibitors market over the forecast period. Chronic diseases such as cancer, cardiovascular diseases, and autoimmune diseases are becoming more prevalent. According to the World Health Organization, chronic diseases are expected to become the seventh leading cause of death globally by the end of 2030. Moreover, according to the National Health Council’s report published in 2019, there were approximately 133 million Americans affected by chronic diseases, estimated to be 40% of the total population of the country. In the USA, the number is expected to reach 157 million by 2020, with 87 million people having multiple conditions. Protein inhibitors are used for the treatment of these diseases attributing to fewer adverse effects and higher efficacy. Therefore, an increasing number of people with chronic diseases are anticipated to propel the demand for protein inhibitors market. The high cost of protein inhibitors used for cancer is anticipated to limit the growth of the protein inhibitors market in the near future. Monoclonal antibodies are a type of protein made in the laboratory to bind substances in the body including cancer cells and are used to treat various types of cancer. Monoclonal antibodies therapies are considered to be costlier when used for cancer. For instance, according to the National Center for Biotechnology Information, the average price of monoclonal antibody was $96,731 for 34 monoclonal antibodies indication combinations. Oncology and hematology monoclonal antibodies represented 40% of approved monoclonal antibodies indication combinations, yet accounted for more than 85% of those priced $100,000 or higher. The price of oncology or hematology monoclonal antibodies was $149,622 higher than those used in metabolic or cardiovascular disorders, $106,830 higher than in ophthalmology, $128,856 higher than in infectious diseases or allergy, and $98,981 higher than in immunology. Thus, the high cost of protein inhibitors including monoclonal antibodies for the treatment of cancer is expected to hinder the market’s growth. Companies in the protein inhibitors market are increasingly investing in various strategic initiatives such as partnerships and collaborations to develop new drugs to meet the market demand. Strategic collaborations and partnership agreements help companies to expand their existing product portfolio and geographical presence. For instance, in February 2020, Catalent, Inc., a USA-based provider of delivery technologies, drug manufacturing, gene therapies, biologics, and consumer healthcare products announced the partnership agreement with Zumutor Biologics Inc., an immune-oncology company based in the USA to manufacture ZM008, a monoclonal antibody targeting solid tumors. Moreover, in July 2018, Anima Biotech, a USA-based biotechnology company announced a partnership agreement with Eli Lilly and Company, a USA-based pharmaceutical company for the development and discovery of translation inhibitors of several protein targets using Anima Biotech's translation control therapeutics platform. In December 2019, Sanofi S.A. is a France-based pharmaceutical company announced the acquisition of Synthorx, Inc., a biotechnology company for $2.5 billion. The acquisition is aimed at boosting the immune-oncology pipeline of Sanofi S.A. Synthorx, Inc.’s novel discovery platform has developed a molecule with the potential to become a foundation for the next generation of combination therapies for the treatment of cancer. THOR-707 by expanding the number of T-cells and natural killer cells in the body can be combined with other oncology medicines for treating cancer. Synthorx, Inc. is a USA-based company specializing in protein therapeutics for improving and prolonging the lives of people with autoimmune diseases, inflammatory diseases, and cancer. The major players covered in the global protein inhibitors market are Bayer AG, Astra Zeneca, Roche, Teva, Apotex, Novartis, Glaxosmithkline, Pfizer, Boehringer Ingelheim, F. Hoffmann-La Roche, Abbott Laboratories, Amgen Inc., Baxter International Inc., Merck & Co. Inc. The countries covered in the global protein inhibitors market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The regions covered in the global protein inhibitors market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global protein inhibitors market is segmented - 1) By Product: Protein Kinase Inhibitors, Monoclonal Antibody, Others 2) By Application: Oncology, Inflammatory Diseases, Others 3) By Distribution Channel: Hospital Pharmacies, Independent Pharmacies, Online Pharmacies

The anemia and other blood disorder drugs market consists of sales of anemia and other blood disorder drugs and related services. Anemia and other blood disorder drugs that are used to stimulate red blood cell production or hemoglobin in the human body include Erythropoietin (Epoetin alpha), Ferrous Sulfate, Iron Dextran, Deferoxamine, Immunosuppressant, Bone marrow stimulants, Corticosteroids, Aminoxin, Hespan, Hextend, and Pyridoxine. The market also comprises of sales of drugs that are responsible for curing other blood disorders, including inherited orphan blood disorder. The global anemia and other blood disorder drugs market is expected to grow from $52.24 billion in 2020 to $53.43 billion in 2021 at a compound annual growth rate (CAGR) of 2.3%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $84.59 billion in 2025 at a CAGR of 12.2%. The increasing prevalence of anemia among the global population acts as a strong driving factor for the market. Unhealthy lifestyles, changing dietary habits and increased stress levels increased the cases of anemia worldwide. For instance, anemia was found to be the most frequent disease in the elderly population (> 65 years of age), reaching a prevalence rate of around 17%. The World Bank reported that anemia is the 8th leading cause of disease among women and the young population. Growth in the prevalence rate of anemia drives the market. There has been an increase in the use of biologics for treating anemia and other blood disorders. Biologics are composed of protein, sugar, nucleic acids, or a combination of these substances or might be derived from living organisms like humans, animals, or microorganisms or that may contain components of living organisms. The growth in the use of biologics over the drugs restricts the market resulting in the decline of the number of drugs being used for the treatment of anemia & other blood disorders. For example, Hospira, a medical device and pharmaceutical company, submitted its first biologics license application to FDA for the approval of a drug that treats anemia. Moreover, the FDA approved the first Epoetin Alfa biosimilar for the treatment of anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in patients with HIV infection. The increase in the use of biologics will hamper the growth of the market. Companies in the anemia and other blood disorder drugs market are collaborating with other companies to develop and commercialize a specific kind of drug by sharing the knowledge, technology, and cost. Such collaborations are also helpful to the companies in case of expiring licenses and stringent regulatory environment. For example, in 2020, Akebia Therapeutics announced a collaboration with Tobacco Inc to treat adult patients with iron deficiency anemia. Another such example is, Akebia Therapeutics Inc. and Otsuka Pharmaceutical Co. Ltd. entered into an agreement to manufacture and commercialize Vadadustat, an oral HIF stabilizer, used for the treatment of anemia. The anemia and other blood disorder drugs market is governed by several regulatory bodies that regulate their functioning by carrying out quality checks for that drug before it can be launched in the market. For instance, the U.S. Food & Drug Administration (FDA) requires every pharmaceutical company to get their drugs examined by the concerned authority. FDA sorts to a Risk Evaluation and Mitigation Strategy (REMS) for determining the safety and quality standards of the drug and grants approvals only if the standards are up to the mark. In 2019, AMAG Pharmaceutical, an American pharmaceutical company agreed to acquire Perosphere for $415 million. The acquisition would result in expanding AMAG's pipeline and enhance its presence in the Hematology drugs market with the help of Perosphere's next-generation Anticoagulant reversal agent called Ciraparantag. Perosphere is a specialty pharmaceutical company focusing on rescue drug medications. The Company was established in 2011 and is headquartered in Danbury, Connecticut, USA. Major players in the market are Amgen Inc., GlaxoSmithKline plc, Akebia Therapeutics, Bayer AG and Pfizer, Inc. The countries covered in the global anemia and other blood disorder drugs market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, Australia. The regions covered in the global anemia and other blood disorder drugs market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global anemia and other blood disorder drugs market is segmented - 1) By Type: Iron Deficiency Anemia, Chronic Kidney Disease Anemia, Sickle Cell Anemia, Aplastic Anemia 2) By Distribution Channel: Hospitals Pharmacy, Online Pharmacy, Pharmacy 3) By Route of Administration: Oral, Injectable 4) By Anemia Type: Microcytic (Low MCV), Normocytic (Normal MCV), Macrocytic (High MCV)